针对正在接受高风险前列腺癌终极放射治疗的男性的治疗强化策略
John Nikitas1, Amar Kishan1, Albert Chang1
1Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
World journal of urology
|March 16, 2024
概括
用外部束放射疗法 (EBRT) 和荷尔蒙疗法强化治疗改善了高风险前列腺癌的结果. 结合EBRT,先进的荷尔蒙疗法和支臂疗法,为这些患者提供了生存益处.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 高风险的前列腺癌需要积极的治疗策略.
- 外部射线疗法 (EBRT) 强化是管理这种疾病的关键组成部分.
研究的目的:
- 审查高风险前列腺癌的基于证据的治疗强化策略.
- 介绍优化放射治疗和激素治疗的新进展.
主要方法:
- 对相关科学文献进行批判性叙事审查.
- 分析当前和新兴的治疗强化方案.
主要成果:
- 将雄激素剥夺疗法 (ADT) 延长至18-36个月,并使用支架疗法增强得到了强有力的证据支持.
- 焦点EBRT增强和添加阿比拉酸到ADT显示承诺.
- 基因组分类器测试和先进的成像可以改善患者选择强化治疗.
结论:
- 结合EBRT,先进的荷尔蒙疗法和支臂疗法可以提高高风险前列腺癌的治疗结果和生存率.
- 个性化治疗决策需要患者和多学科瘤团队之间的合作.
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Disorders of the Male Reproductive System
409
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
409
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


